Insulin injection technique is not a cosmetic detail — it is half the dose. The number you dial on the pen is an intention. The actual dose is whatever the tissue under your skin absorbs. When a repeatedly-used injection site turns into hardened, overgrown tissue, absorption becomes slow and unpredictable: readings run high for no reason, then crash for no reason. And the person living it usually blames their food or their own discipline, when the problem is where the needle went.
This article explains what lipohypertrophy is, why "I move the needle around" is not the same as rotating, and what correct rotation actually looks like under the latest international recommendations. It also carries one warning that should not be skipped: fixing your injection sites may require lowering your insulin dose, and that is done only with your doctor.
What actually decides how your dose works?
Insulin is injected into the fat layer just beneath the skin — not into muscle, and not into the skin itself. That layer is not merely a storage cupboard; it is what releases insulin gradually into the bloodstream. Change the nature of that tissue and you change the release rate, which changes the effect of the dose without changing the number on the pen.
Here is the key to the whole article: a "correct" dose injected into damaged tissue is not a correct dose. You may have counted the carbohydrate in your meal precisely, timed it well, and followed exactly what your doctor prescribed — and still get a reading that defies every expectation, because the variable nobody accounted for was the tissue that received the needle.
What is lipohypertrophy, and why might you not see it in the mirror?
Lipohypertrophy is the enlargement and proliferation of fat cells under the skin caused by repeatedly injecting into the same area. Insulin is an anabolic hormone by nature, so when one small patch of skin receives repeated doses, the tissue responds by growing — and gradually becomes a mass that is firmer and less elastic than the normal fat around it.
The UK's FIT guidance describes the clinical appearance plainly: the area shows "a raised or mound-like, convex pattern," and on palpation feels "harder, and more rubbery or less bouncy" than neighbouring tissue. The trouble is that these are the signs of the late stage, not the early one.
The lump you can feel is already the late stage
Commenting on the newest international recommendations, Dr. David Klonoff compressed the problem into a sentence worth reading twice: "if you can feel it, you already have a serious problem." Touch, in other words, is a late instrument. By the time a lump is palpable under your fingers, the tissue changed a long time ago.
This is precisely why the FITTER Forward recommendations, published in Mayo Clinic Proceedings on 2 April 2025 — the group's first update since 2016 — now recommend ultrasound screening rather than relying on palpation alone.
Why do the numbers vary so wildly?
The gap between what a hand finds and what ultrasound finds is the entire story. In a narrative review published in Diabetology in 2025 (Strollo, Guarino and Gentile), estimates based on clinical examination ranged from "2% to 68%" depending on the identification method, while studies that used ultrasound reported "86.5%." The same review cites a meta-analysis of 26,865 patients that arrived at "41.8% (95% CI: 35.9–47.6%)" by clinical examination.
Then, on 27 January 2026, BMC Public Health published a systematic review and meta-analysis (Zhang and colleagues) covering 18 cross-sectional studies and 7,139 patients on insulin. The pooled prevalence of ultrasound-detected lipohypertrophy was 70.5% (95% CI: 61.1%–80.0%).
That figure has to be read with its brakes on. Heterogeneity between studies was very high (I² = 98.8%), and the authors themselves close by urging that "health care administrators and researchers should unify the ultrasound diagnostic criteria and standardize operating procedures to accurately understand the true prevalence." So 70.5% is not a precise census of everyone on insulin. It is a range that says one clear thing: this problem is far more common than our fingers can detect.
Why does overgrown tissue ruin your dose?
Normal fat absorbs insulin in a reasonably predictable pattern. Lipohypertrophic tissue, according to the Diabetology review, absorbs it in a way that is "slower and more unpredictable than normal fat tissue, which may result in excessive insulin doses required to achieve a pharmacological effect."
The word "unpredictable" is more dangerous than the word "slower." Slow alone can be managed with a larger dose. Unpredictable means the same dose in the same spot may be absorbed sluggishly today and released all at once tomorrow. That is exactly the pattern so many people describe: unexplained highs, followed by unexplained lows.
The numbers support it. The Diabetology review reports that "46.2% of patients with LHs experienced one or more episodes of hypoglycemia compared with 6.8% of those without LHs." The UK FIT guidance points the same way, noting that "39.1% had unexplained hypoglycaemia and 49.1% had glycaemic variation."
And the dose cost is documented too: people with lipohypertrophy require higher insulin doses on average — roughly 21 extra units in type 1 diabetes and 8 extra units in type 2. Which means part of what looks like "resistance" to a dose may not live in the whole body at all, but in a few square centimetres of skin.
One more figure deserves a pause. Injecting into the affected area happens in up to "55.3%" of people with diabetes on insulin. The reason is simple and quietly cruel: the overgrown area is often less sensitive to pain, so people unconsciously come to prefer it. The body steers its owner toward the wrong site precisely because it is the site that hurts least.
"I rotate my injection sites" — why isn't that enough?
In the largest international survey of injection technique, conducted in 2014–2015 across 42 countries with 13,289 participants, the gap showed up starkly: "Worldwide, 83.9% reported rotating their injection sites, and 70.6% did so correctly per nurse inspection." A meaningful share of people who believe they rotate are not rotating in the way that actually protects tissue.
The Saudi picture mirrors it. A cross-sectional study published in PeerJ in 2025 (Alavudeen and colleagues) surveyed 187 insulin users in the southern region of the Kingdom. 87% said they practised site rotation — yet 38% reported "swelling or lumps under the skin at usual injection sites," 35% reused needles, and 28.9% had received no training at all (only 2.7% were trained by a pharmacist). The authors' conclusion is verbatim: "Consistent education and re-education are necessary for the insulin users to resolve the issues associated with suboptimal IIT."
Put the two findings together and the lesson is this: "rotating" is a word, not a plan. Rotation that protects tissue is not drifting to an adjacent patch when you happen to remember — it is a written geometric scheme, consistently followed. And this is not an accusation aimed at anyone: a person who was never given a system cannot be blamed for not following one.
What does correct rotation actually look like?
The international recommendations converge on four rules:
- Divide each region into quadrants. FITTER Forward 2025 states that the "body should be divided into quadrants; the injection quadrant should be rotated every three to four days." The UK FIT guidance suggests "dividing the injection site into quadrants using one per week and moving quadrant to quadrant in a consistent direction (e.g. clockwise)." The difference between "every 3–4 days" and "weekly" is a detail; what matters is that the direction is fixed and decided in advance rather than improvised.
- Keep at least 1 cm between each injection and the last. FITTER Forward states that "each injection should be at least 1 cm away from previous sites," matched by FIT UK's "injections should be systematically rotated in such a way that they are spaced at least 1cm from each other."
- Don't return to the same point for weeks. FIT UK recommends that a single point be used "no more frequently than every 4 weeks when feasible."
- Write the scheme down; don't trust memory. A system that isn't recorded reverts within a fortnight into a habit that returns you to your favourite spot — which is usually the least painful one, and therefore the most damaged one.
The choice of region matters too. FIT UK notes that absorption speed varies by site and insulin type: "The abdomen is the preferred site for soluble human insulin since absorption of this insulin is fastest there," while the "thigh or buttock as these sites have slower absorption of NPH" is preferred for an evening NPH dose to reduce the risk of nocturnal hypoglycaemia; rapid-acting analogues are less site-dependent. Hence the practical rule: rotate within a region, not randomly between regions — moving from abdomen to thigh at the same time of day changes the action curve, not just the location.
Small details that change the outcome
- Needle length: 4 mm for everyone. FITTER Forward 2025 states that "the recommended needle length is 4 mm for all individuals, regardless of age or BMI." Needles longer than 5 mm are not recommended because they raise the risk of intramuscular injection, which "can lead to variable blood glucose levels."
- Angle: 90 degrees. With a 4 mm needle the injection goes in perpendicular to the skin, not at 45 degrees.
- Skin lift: for specific groups. FITTER Forward recommends lifting a skin fold to minimise intramuscular risk in older adults (over 60), people with a low BMI (under 19), pregnant women, and children.
- Do not reuse needles. The wording is explicit: "Reusing needles is not recommended," and FIT UK links reuse to an increased presence of lipohypertrophy. Pen needles "are designed to be used only once."
- Prime the pen. FIT UK advises priming "using a two unit air shot" before injecting, to confirm unobstructed flow and clear the needle's dead space.
- Count to ten before withdrawing. "After pushing the thumb button completely in, patients should count slowly to 10 before withdrawing the needle" — otherwise part of the dose can leak back out.
- Cold insulin adds to the harm. The 2025 recommendations link cold insulin and needle reuse to increased lipohypertrophy risk, and advise storing unopened insulin refrigerated at roughly 2–8°C (36°F to 46°F).
The most important paragraph here: what happens when you move to healthy tissue?
This section is why the warning sits at the top of the article, and it should not be skipped.
If you have been injecting into an overgrown area for months, your body has adapted to slow, incomplete absorption — and your current dose has been calibrated, without anyone intending it, around that shortfall. Move suddenly to healthy tissue that absorbs insulin at its normal efficiency and you have not merely changed a location; you have sharply raised the effective dose.
FIT UK says it outright: "Switching injections from lipohypertrophic to normal tissue often requires a decrease in the dose of insulin injected. The amount of change varies from one individual to another." It adds that patients should be supported "to reduce their insulin doses in line with glucose results, knowing that reductions often exceed 20% of their original dose," and encouraged "to monitor glucose levels frequently due to the risk of unexpected hypoglycaemia."
So the practical message is not "move to a clean site tomorrow." It is: do not move your injections to healthy tissue while keeping the same dose without going back to your doctor or diabetes educator. The move is a treatment decision that needs a dose-reduction plan and more frequent monitoring in the first days — not a well-intentioned step taken alone.
How do you examine your own injection sites?
Self-examination does not replace your doctor, but it opens the right conversation with them. The method is simple:
- Check in good light, standing and then lying down; some lumps appear in one position and vanish in another.
- Look first: search for any raised or convex swelling compared with the neighbouring skin.
- Then feel: run your fingertips with light pressure, compare left with right, and look for an area that is firmer or less elastic than its surroundings.
- Notice the silent clue: any spot where you inject and feel almost nothing deserves suspicion, not preference.
- Write down what you find and show your doctor. If your readings swing without explanation despite your adherence, ask directly about an ultrasound assessment of your injection sites — per the 2025 recommendations it is more accurate than palpation.
The recommendations also carry a piece of practical good news: "sites with lipohypertrophy tend to decrease in size when rotation is implemented." The tissue can improve when it is given organised rest — over weeks to months, not days.
When should you call your doctor, and who should be extra careful?
See your doctor or diabetes educator — and do not adjust your dose on your own — in these situations:
- A lump, firmness, or change in skin texture at any of your injection sites.
- Unexplained swings in blood sugar despite consistent food, medication and activity.
- Repeated hypoglycaemia, especially at night or without an obvious cause. The CDC defines low blood sugar as "below 70 mg/dL," and considers below "54 mg/dL" severe, low enough that it "may make you faint." Symptoms include: "Fast heartbeat. Shaking. Sweating. Nervousness or anxiety. Irritability or confusion. Dizziness. Hunger."
- Signs of severe hypoglycaemia needing someone else's help: "Feeling weak. Having trouble walking or seeing clearly. Acting strange or feeling confused. Having seizures."
- Redness, warmth, persistent pain or discharge at an injection site (possible infection).
- Persistently high readings alongside worrying general symptoms — a situation that needs urgent medical assessment, and one we covered separately in our article on ketones and when they become an emergency.
Extra attention is warranted for: anyone who has used insulin for years, anyone injecting more than three times a day, anyone reusing needles, anyone who never received formal injection training, children and adolescents and those who inject on their behalf, older adults, and pregnant women. The same site-selection and rotation rules apply to other medicines given subcutaneously by pen — one class of which we covered in our article on GLP-1 medications.
This article is educational and does not replace your doctor's advice. Any change to your dose or your injection sites should happen under the supervision of the medical team following your case.
Where does Bakery 8 fit into this?
Let's start with what we cannot claim: no bread improves how your tissue absorbs insulin, and no product in our store replaces your doctor or a corrected injection technique. Everything above concerns the needle and the skin, and food has nothing to do with it.
But there is one honest claim worth making. Blood sugar control is an equation with two sides: medication and food. When the medication side is unpredictable because of the tissue, it becomes hard for anyone — including your doctor — to interpret your readings. The reverse is also true: the steadier and more estimable the carbohydrate side, the easier it is to notice that the problem is not the meal. A daily base that is low in carbohydrate and free of sugar keeps that side quieter and simpler to count.
In our bread section, samoli bread and cloud bread remain a steady daily option for anyone who wants a loaf whose numbers they already know; in the granola section, keto granola suits a repeatable breakfast that doesn't surprise you; and for something sweet with no added sugar there is the desserts section. If you want to understand how to count that side precisely, our earlier article on counting net carbs walks through the method step by step.
Frequently asked questions
Is lipohypertrophy permanent? Does it go away?
Not necessarily permanent. The FITTER Forward 2025 recommendations note that "sites with lipohypertrophy tend to decrease in size when rotation is implemented." But improvement requires resting the area for weeks to months with consistent rotation, not days. And you should not rest the area and move to healthy tissue without a dose-reduction plan agreed with your doctor.
Is it enough to alternate between abdomen and thigh each day?
No, and it may do harm. Absorption speed for some insulin types differs by region, so switching region daily changes the action curve, not just the location. The practical rule is to keep each dosing time in its usual region, then rotate within that region with at least 1 cm between one injection and the next.
Exactly how much distance and time are needed?
At least 1 cm between each injection and the previous one; divide the region into quadrants and move between quadrants every three to four days per the 2025 recommendations, or weekly per FIT UK; and avoid returning to the same point more often than every four weeks when feasible. More important than the exact number is that the direction is fixed and written down.
Is reusing a needle just once acceptable?
The international recommendation is explicit: reusing needles is not recommended, and pen needles are designed for single use. The evidence links reuse to increased lipohypertrophy. It has been observed that pain does not increase appreciably up to about five uses — but the absence of pain is not evidence of safety, because the damage here happens in the tissue, not in the sensation.
My readings swing despite total adherence. Does that mean the problem is my injections?
Not necessarily — swings have many causes. But injection sites are among the most neglected possibilities and the easiest to check, and asking costs nothing. Examine your sites, write down what you find, and raise it with your doctor before assuming the problem is your discipline.
Do I really need an ultrasound?
That is a medical decision, not a self-directed one. But if your readings are unexplained and your self-examination looks clear, it is reasonable to ask your doctor about it, because palpation misses smaller and shallower lesions — which is exactly why the 2025 recommendations prefer ultrasound.
The bottom line
Injection technique is the cheapest available improvement in insulin therapy: it needs no new drug and no new device, just a written rotation scheme, a short needle used once, and an eye that checks the skin regularly. And if you find something, the next step is not an immediate change of site — it is a conversation with your doctor about lowering the dose safely.
At Bakery 8 / مخبز ثمانية (Riyadh, Saudi Arabia) we work on only the other side of that equation: making what you eat daily steady and known, so there are fewer surprises left over. Browse our products if you want a quieter daily base.
References
- Klonoff DC, Berard L, Franco DR, et al. "Advance Insulin Injection Technique and Education With FITTER Forward Expert Recommendations." Mayo Clinic Proceedings, 2 April 2025.
- Healio. "Guidance details proper insulin injection technique for people with diabetes" — coverage of the FITTER Forward recommendations with comments from Dr. David Klonoff, 23 April 2025.
- Zhang Q, Zhu Y, Wang L, Xiao L, Gao F, Jia P, Tang X. "Prevalence of insulin injection-induced lipohypertrophy detected by ultrasound: a systematic review and meta-analysis." BMC Public Health, Volume 26, Article 663, 27 January 2026.
- Strollo F, Guarino G, Gentile S. "A Neglected Complication of Insulin Therapy Due to Errors in Injection Technique: Skin Lipohypertrophies: A Narrative Review." Diabetology, 2025; 6(3):22.
- FIT UK Forum for Injection Technique. "UK Injection and Infusion Technique Recommendations," 5th Edition, October 2019.
- Calliari LE, Cudizio L, Tschiedel B, Pedrosa HC, Rea R, Pimazoni-Netto A, Hirsch L, Strauss K. "Insulin Injection Technique Questionnaire: results of an international study comparing Brazil, Latin America and World data." Diabetology & Metabolic Syndrome, 2018.
- Alavudeen SS, et al. "A cross-sectional study evaluating insulin injection techniques and the impact of instructions from various healthcare professionals on insulin users in the southern region of Saudi Arabia." PeerJ, 2025; article e19394.
- Frid AH, Kreugel G, Grassi G, et al. "New Insulin Delivery Recommendations." Mayo Clinic Proceedings, 2016 — the prior recommendations updated by FITTER Forward.
- Centers for Disease Control and Prevention (CDC). "Low Blood Sugar (Hypoglycemia)."
Related keywords: insulin injection technique, insulin injection site rotation, lipohypertrophy, lumps under the skin from insulin, 4 mm insulin needle, insulin needle reuse, unexplained hypoglycemia, insulin injection sites, insulin injection complications, reducing insulin dose when changing sites.